Review of Contemporary Philosophy
ISSN: 1841-5261, e-ISSN: 2471-089X
Vol 22 (1), 2023
Pp 5025 - 5037

Meige Syndrome: An Updated Overview, Pharmacological Treatment, Management, And Nursing Interventions

[1]-Elham Ahmed Mobarki,[2]-Meshari Mohammad Aljasim ,[3]-Ali Mohammed Albgami,[4]-Mubarak Fahad Aldosari ,[5]-Saeed Abdullah Mohammed Alqahtani,[6]-Saad Mohammed Saad Lajhar,[7]-Fysal Mohammad Saeed Alshahrani,[8]- Ali Edris Abeeri,[9]-Huda Ahmad Haj Atti,[10]-Hashima Makki Mohammed Jabour ,[11]-Zahraa Qasem Alnakhli,[12]-Amani Gassim Ghalfan Khormi

[1] Ksa, Ministry Of Health
[2] Ksa, Ministry Of Health, Hassan Al-Afaliq For Long-Term Care Hospital
[3] King Saud Medical City Ksa, Ministry Of Health,
[4] Ksa, Ministry Of Health, Alsulayyil General Hospital
[5] Ksa, Ministry Of Health, Khamis Mushayt Maternity And Children's Hospital
[6] Ksa, Ministry Of Health, Ahad Rafidah General Hospital
[7] Ksa, Ministry Of Health, Ahad Rafidah General Hospital
[8] Ksa, Ministry Of Health, Almuwassam General Hospital In Jizan
[9] Ksa, Ministry Of Health, Erada Hospital And Mental Health
[10]Ksa, Ministry Of Health, Ksa Dammam
[11]Ksa, Ministry Of Health, King Salman Bin Abdulaziz Medical City
[12]Ksa, Ministry Of Health, Gizan General Hospital

Abstract:

Background: Meige syndrome is a rare focal dystonic disorder characterized by blepharospasm (involuntary eyelid spasms) and oromandibular dystonia (spasms of jaw and facial muscles). First described by Dr. Henry Meige in 1910 and later named by Dr. George Paulson in 1972, the syndrome's exact pathophysiology remains unclear. It is thought to arise due to dysfunctions in neurotransmitter systems, particularly dopamine and gamma-aminobutyric acid (GABA), involving the basal ganglia, a critical brain region for motor control.

Aim: This review aims to provide an updated understanding of Meige syndrome, including its pathophysiology, clinical presentation, pharmacological treatment options, and management strategies, as well as nursing interventions to improve patient outcomes.

Methods: A comprehensive review of relevant literature was conducted, focusing on primary and secondary causes of Meige syndrome, its epidemiology, pathophysiology, and treatment strategies. Various pharmacological treatments, including botulinum toxin injections and dopaminergic therapy, were discussed alongside the latest findings in genetic and environmental factors contributing to the disorder.

Results: Meige syndrome predominantly affects individuals between the ages of 30 and 70, with a higher incidence in females. Symptoms typically begin with dystonia of the jaw and face and may progress to include neck and other muscles. Genetic mutations (e.g., in the GNAL and TOR1A genes) and environmental factors (such as stress or neuroleptic drug use) contribute to its onset. Pharmacological treatments like botulinum toxin injections and dopamine-modulating drugs show promise in managing symptoms. Physical therapy and psychosocial support are essential for comprehensive care.

Conclusion: Although the pathogenesis of Meige syndrome remains complex, pharmacological and non-pharmacological treatments can significantly improve symptom management. Ongoing research into genetic and environmental interactions is necessary to develop more effective therapies. Multidisciplinary

management, including nursing interventions, plays a crucial role in enhancing quality of life for individuals with Meige syndrome.

Keywords: Meige syndrome, dystonia, blepharospasm, oromandibular dystonia, pharmacological treatment, nursing interventions, basal ganglia, neurotransmitters, botulinum toxin.

Received: 05 October 2023 **Revised**: 19 November 2023 **Accepted**: 02 December 2023

Introduction:

Meige syndrome is a focal dystonic movement disorder characterized by blepharospasm (spasms of the eyelids) and oromandibular dystonia. Dystonia refers to abnormal, involuntary posturing or movements resulting from sustained muscle contractions, which are often associated with neurological or medical causes [1]. In 1910, Dr. Henry Meige, a French neurologist, observed abnormal contractions of the midline facial muscles, including involuntary eyelid closure, in approximately ten patients. He initially referred to this condition as "spasm facial median" [2][3]. These patients also exhibited similar clinical manifestations in the muscles of the jaw and oropharynx. In 1972, Dr. George Paulson coined the term "Meige syndrome" to describe patients with facial muscle spasms, particularly blepharospasm and dystonia of the oromandibular muscles [4]. Later, Gilbert introduced the term "Brueghel syndrome" to describe cases of jaw dystonia without blepharospasm, distinguishing it from Meige syndrome [5][6]. The use of the term "Meige syndrome" for this type of dystonia is sometimes problematic and confusing, particularly because Dr. Meige himself did not suffer from the syndrome and was not the first to describe it [4]. Medical organizations, such as the Council of Science Editors, have advised against using possessive forms of eponyms [7][8]. Moreover, Meige syndrome is occasionally confused with Meigs' syndrome, a condition unrelated to dystonia that pertains to a specific type of benign ovarian tumor [9].

Although the precise pathophysiology of Meige syndrome remains unknown, it is thought to be associated with abnormalities in the basal ganglia, a critical brain region involved in motor control [10]. Dystonia is believed to result from dysfunction in neurotransmitter systems, particularly dopamine and gamma-aminobutyric acid (GABA) [11]. The progression of Meige syndrome varies considerably from one individual to another. Symptoms often begin gradually and may worsen over time, though they can also spontaneously remit or stabilize. The age of onset also varies; some individuals exhibit symptoms in early adulthood, while others may not experience them until later in life. The management and treatment of symptoms can be challenging due to their unpredictable nature and their impact on daily functioning [12]. The lower face and jaw typically present the initial signs of Meige syndrome. These early symptoms manifest as involuntary spasms in the muscles responsible for speech, swallowing, and chewing. Over time, dystonic movements may extend to the lips, tongue, cheeks, and neck muscles, as well as other parts of the face [13]. In some cases, dystonia may progress to affect other parts of the body, resulting in generalized dystonia, though in other cases, it remains confined to the oromandibular region.

Etiology

Primary Meige Syndrome:

Primary Meige syndrome manifests without an identifiable underlying cause, typically presenting as isolated dystonic movements of the face and jaw. In contrast, secondary Meige syndrome arises due to identifiable triggers such as medications, neurodegenerative diseases, or structural brain lesions, often accompanied by additional neurological symptoms or signs pointing to the underlying cause.

Primary Meige Syndrome:

Most cases of Meige syndrome are classified as idiopathic, with the exact cause of the condition still unknown. However, various factors, including genetic, environmental, and neurochemical influences, have been associated with its pathophysiology. Hereditary factors have been suggested to play a role in the development of Meige syndrome, with studies pointing to the potential significance of genetic components in the disease's etiology. Meige syndrome has occasionally been observed to run in families, implying a hereditary susceptibility to the condition. Clinical manifestations of Meige syndrome have been noted in

patients with mutations such as p.Gly213Ser or p.Ala353Thr. Recent research suggests that mutations in the GNAL gene, which encodes the guanine nucleotide-binding protein G, subunit alpha, are linked to cranial and cervical dystonia. However, further studies are required to substantiate this association [15][16]. Studies involving first-degree relatives of individuals with Meige syndrome have demonstrated a penetrance rate of approximately 20%, which may suggest an autosomal dominant inheritance pattern [17]. The inheritance of Meige syndrome is likely complex, influenced by both environmental factors and multiple genetic factors. Similar to other forms of dystonia, Meige syndrome has been associated with mutations in genes such as TOR1A (DYT1), THAP1, and GNAL, which are involved in neurotransmitter regulation and neuronal excitability [18][19].

Secondary Meige Syndrome:

While hereditary factors may predispose individuals to Meige syndrome, environmental triggers can also contribute to the onset or exacerbation of symptoms. These triggers include psychological stress, exposure to specific drugs or toxins, and physical trauma, such as surgery or brain injury [20]. The precise mechanisms by which these environmental factors influence the development of dystonia remain unclear, but they are likely to interact with genetic predispositions. The dysfunction of the basal ganglia and associated neuronal circuits plays a central role in the pathogenesis of Meige syndrome. Disruptions in the levels or activities of neurotransmitters such as glutamate, GABA, and dopamine have been implicated in the development of dystonia, as these neurotransmitters are essential for motor control. Individuals with dystonia, including those with Meige syndrome, often show structural abnormalities or alterations in brain regions critical to motor function, such as the thalamus, sensorimotor cortex, and basal ganglia. These anomalies likely contribute to dystonic symptoms by disrupting the normal operation of motor circuits.

Prolonged use of neuroleptic medications, which affects about one-quarter of patients, can lead to alterations in receptor function, contributing to facial or cervical dystonia. This phenomenon, known as denervation hypersensitivity, is thought to result from increased central dopaminergic activity, which can improve with dopamine-depleting agents. Medications that elevate central dopamine activity, including antiemetics (e.g., metoclopramide), antipsychotics, antidepressants, selective serotonin reuptake inhibitors, antihistamines, and dopaminergic agonists, may exacerbate the condition. Other factors such as head trauma, stroke, brainstem demyelination, normal pressure hydrocephalus, cerebral hypoxia, bilateral thalamotomy, kernicterus, space-occupying lesions, and postencephalitic changes have also been implicated in the development of Meige syndrome [20]. Additionally, Meige syndrome may be associated with other movement disorders, including Parkinson's disease, Wilson’s disease, olivopontocerebellar atrophy, and Lewy body disease [21]. Understanding the complex interactions of genetic, environmental, and neurochemical factors involved in the development of Meige syndrome is crucial for developing targeted treatment strategies aimed at alleviating symptoms and enhancing the quality of life for those affected.

Epidemiology

Meige syndrome is comparatively rare when juxtaposed with other movement disorders. It presents a diverse array of clinical manifestations, predominantly characterized by segmental myodystonia, which leads to blepharospasm and abnormal muscular activity in the oromandibular and cervical regions [22]. The typical age range for individuals affected by Meige syndrome spans from 30 to 70 years, with a mean age of 55.7 years, although there have been documented cases in adolescents [23]. Research indicates that the condition tends to manifest predominantly in the sixth decade of life [24][25]. Prevalence estimates for isolated blepharospasm and craniocervical dystonia vary, ranging from approximately 2% to 20% [26]. Crude prevalence estimates for blepharospasm and segmental dystonia vary between 16 and 133 cases per million individuals [27][28].

The sex ratio for Meige syndrome remains inconsistent across various studies, with a general tendency toward a higher incidence in females. Some research indicates an equitable distribution between the sexes, while others report a female-to-male ratio of roughly 2:1 [29]. The increased prevalence among females could be attributed to factors that are yet to be fully understood, potentially linked to hormonal influences,

environmental factors, or genetic predispositions [30]. One hypothesis suggests that estrogen receptors in females may predispose them to involuntary muscle spasms [31]. Meige syndrome has been documented across the globe; however, the frequency of reporting and detection may vary based on factors such as geographic location, accessibility to healthcare facilities, diagnostic capabilities, and levels of awareness. While extensive population-based studies on the incidence of Meige syndrome are scarce, case reports and clinical series from countries spanning North America, Europe, Asia, and other continents have been published. Research conducted in the United States indicates prevalence estimates ranging from 13 to 130 cases per million, while European studies suggest prevalence rates around 36 per million [32].

Pathophysiology

Meige syndrome is characterized by abnormalities within the basal ganglia-thalamocortical motor circuitry, resulting in abnormal postures and involuntary muscle contractions, akin to other forms of dystonia. Current research suggests that disruptions in sensory-motor integration, alterations in cortical excitability, and dysfunction in neurotransmitter systems may contribute to the pathophysiological underpinnings of Meige syndrome, although the precise mechanisms remain unclear. The key neurotransmitters involved in regulating motor function within the basal ganglia-thalamocortical circuitry include dopamine, glutamate, and GABA. Dysregulation of these neurotransmitter systems has been implicated in the pathophysiology of Meige syndrome. The prevailing theory posits that dopaminergic and cholinergic hyperactivity may contribute to the development of the disorder, though it is also believed that reduced function of inhibitory neurons, such as GABAergic neurons in the cortex, could play a role. Dystonia is thought to stem from decreased dopamine signaling in the basal ganglia, particularly within the striatum. Dysfunction in the dopaminergic pathway disrupts the balance between direct and indirect pathways, leading to increased neuronal firing and abnormal muscle contractions [33]. GABA, the brain's primary inhibitory neurotransmitter, plays a critical role in modulating neuronal excitability [34]. Changes in GABAergic signaling, such as deficiencies in GABA production, release, or receptor function, may result in abnormal neuronal activity within the basal ganglia and cortical motor regions, exacerbating dystonic symptoms. Glutamate, the principal excitatory neurotransmitter in the central nervous system, facilitates synaptic transmission within the basal ganglia-thalamocortical circuitry [35].

Several environmental and genetic factors predispose individuals to craniocervical dystonia. Some studies propose that patients with this condition exhibit abnormal sensorimotor processing, as indicated by positron emission tomography scans revealing reduced blood flow to the sensorimotor area in response to lower facial vibrations. Silent functional magnetic resonance imaging (fMRI) has demonstrated decreased activation within the primary motor cortex (Brodmann area 4) and premotor cortex (Brodmann area 6) in patients with isolated blepharospasm. This reduced activity may stem from disrupted regulation of cranial nerve nuclei in the brainstem by the basal ganglia. Brain imaging has identified a reduction in gray matter volume within the cerebellum, superior frontal gyrus, insular cortex, and calcarine fissure in patients with craniocervical dystonia [36][37]. Focal dystonias also exhibit a genetic component in their etiopathogenesis. On the cellular level, mutations in the TOR1A gene appear to impair vesicular trafficking into and out of the nucleus, leading to transcriptional dysregulation [38][39]. A similar mechanism is involved in other primary focal dystonias, such as mutations in central nervous system transcriptional factors, including TAF1 and THAP1 [40]. Studies involving both animal and human models provide evidence of specific genetic mutations that may contribute to the disrupted development of neuronal networks.

History and Physical

The presentation of Meige syndrome varies considerably among patients. Symptoms may initially present as unilateral blepharospasm, later progressing to bilateral involvement [see Video: Typical Blepharospasm]. One of the most challenging aspects of Meige syndrome is its diverse phenotypic manifestations, which range from tonic spasms or prolonged eyelid closure to complete inability to open the eyes. Eyelid weakness, or blepharoptosis, is also frequently observed [25]. The condition is characterized by progressive muscular dysfunction, typically beginning as focal neurological dysfunction such as essential blepharospasm or oromandibular dystonia, eventually affecting additional muscle groups.

Muscles of the neck (antecollis, retrocollis, and torticollis), respiratory muscles, or upper limb muscles (leading to dystonic tremors) may become involved [41]. Frequently implicated oromandibular muscles include the temporalis, masseter, and platysma. Involuntary movements of the lower face and masticatory muscles may include lip pursing, chewing, grimacing, jaw thrusting, and jaw opening or clenching actions [42].

Patients often report a gradual onset of symptoms, typically beginning with occasional jaw clenching or facial twitching. Over time, the frequency and severity of involuntary movements and atypical postures tend to escalate, signifying the progression of the disorder [25]. Studies indicate that the spread of dystonic contractions to adjacent muscle groups is most probable within the first year of symptom onset, with this risk continuing for 3 to 5 years. In individuals with blepharospasm, factors such as older age at symptom onset, female sex, and a history of head trauma are linked to an increased likelihood of symptom spread [43]. Many patients with Meige syndrome employ sensory tricks, which are sensory stimuli that they learn to use to alleviate dystonia symptoms. Common examples of these tricks include resting, relaxing, talking, pulling the upper eyelid, blowing air into the cheeks, walking, exposure to cold water, yawning, or drinking liquids [44]. More than half of those with blepharospasm utilize one or more sensory tricks [42]. Additionally, patients may identify specific behaviors (e.g., speaking or eating) or environmental factors (e.g., stress, fatigue, and caffeine) that exacerbate their symptoms. Identifying these triggers can provide valuable insights into treatment decisions and help inform our understanding of the pathophysiology of Meige syndrome.

A thorough medical history is essential for assessing the risk of Meige syndrome. This includes inquiring about any history of drug use, neurological conditions, or prior head injuries. A family history of dystonia or other movement disorders may suggest a genetic predisposition to the condition. The physical examination of individuals with Meige syndrome typically reveals characteristic clinical signs, including involuntary muscular spasms in the face, jaw, and neck. A comprehensive history and physical examination are critical to guide further evaluation and management. Additionally, it is essential to assess associated symptoms, functional limitations, and potential triggers or exacerbating factors. A detailed neurological examination is necessary to assess reflexes, coordination, gait, motor function, and sensory trick efficacy. The presence of bradykinesia, tremors, dystonic movements, or other neurological signs warrants further investigation to rule out underlying neurological disorders.

Evaluation

Assessing Meige syndrome is essential for establishing a definitive diagnosis, identifying potential underlying etiologies, and guiding appropriate treatment strategies. The evaluation of Meige syndrome necessitates a thorough, multifaceted approach, encompassing clinical assessment, neuroimaging, and laboratory investigations. Given that there is no single test that can confirm the diagnosis of Meige syndrome, a comprehensive evaluation is critical to exclude other possible causes and assess the severity of the condition. Brain magnetic resonance imaging (MRI) plays a pivotal role in excluding structural abnormalities that may either resemble or exacerbate dystonic symptoms, such as tumors, vascular malformations, or other lesions [45]. While brain MRI findings in Meige syndrome are often unremarkable, imaging can be valuable in particular cases to differentiate secondary causes of dystonia. In addition, MRI and/or computed tomography (CT) scans of the brain can assist in ruling out stroke as a potential underlying cause. Electrophysiological investigations contribute significantly to the differential diagnosis of Meige syndrome. Nerve conduction studies and electromyography (EMG) provide critical information regarding muscle activation patterns and can help to exclude other neuromuscular disorders that may be misinterpreted as dystonia [46]. Surface EMG recordings are particularly useful in assessing the type and intensity of myofascial contractions in individuals with Meige syndrome.

Genetic testing is an important consideration when there is a family history of dystonia or a suspected genetic predisposition [47]. Targeted sequencing or panel testing of genes associated with dystonia, such as TOR1A (DYT1), THAP1, and GNAL, can help identify pathogenic mutations that may be responsible for Meige syndrome [32][48]. Metabolic and toxicological screening is critical in cases where unusual

symptoms are present or secondary dystonia is suspected. Laboratory testing for metabolic disorders, such as Wilson disease or mitochondrial abnormalities, may be indicated. Moreover, investigating exposure to chemicals or drugs known to induce dystonia is crucial. The workup should include a serum drug screen, SSA/SSB levels, copper and ceruloplasmin levels, uric acid levels, and the Beck Depression Inventory [49]. The European Federation of Neurological Societies (EFNS), the American Academy of Neurology, and other international organizations have published clinical guidelines for diagnosing and managing movement disorders. These recommendations offer valuable insights into the diagnostic and therapeutic approaches for Meige syndrome, incorporating the latest research findings and best practices [50].

Treatment / Management

The management of Meige syndrome aims to alleviate symptoms, improve functional outcomes, and enhance the quality of life for affected individuals. Treatment strategies typically involve a combination of pharmacological interventions, botulinum toxin injections, surgical options, and supportive therapies. Oral medications, such as muscle relaxants, dopamine receptor antagonists, and anticholinergic drugs, are commonly employed to address dystonic symptoms in Meige syndrome [51]. These medications target muscle spasms and aim to improve motor function, although their effectiveness may vary across individuals. A deeper understanding of the pathophysiology of Meige syndrome underscores the utility of medications like anticholinergics (e.g., trihexyphenidyl), dopamine antagonists (e.g., tiapride and tetrabenazine), and GABA receptor agonists (e.g., benzodiazepines) in managing these symptoms [4]. In addition to the above, antiepileptic drugs (e.g., valproic acid) and various psychoactive medications are also used in the management of Meige syndrome. Drugs like eszopiclone and nitrazepam target specific subunits (omega-1 and omega-2) of the GABA receptor complex, providing relief from eyelid spasms. Case reports have indicated that zolpidem may also be effective, owing to its high specificity for the GABA omega-1 receptor. Prolonged use of psychoactive drugs can sometimes induce eyelid spasming, which is more commonly associated with typical antipsychotics, though reports also suggest that the use of olanzapine can exacerbate blepharospasm [53].

Botulinum toxin injections offer an effective treatment modality for blepharospasm and facial dystonia [54]. Botulinum toxin A (also known as onabotulinumtoxinA or abobotulinumtoxinA) injections have shown significant promise, particularly in patients who fail to respond to oral medications or who experience adverse effects from these treatments [55]. Injections are administered to the affected muscles to induce temporary chemical denervation, thereby reducing muscular hyperactivity [56]. Typically, treatment is administered every two to six months, depending on the individual's response and symptom severity [57]. However, repeated and prolonged use of botulinum toxin A injections can lead to the development of therapeutic resistance due to antibody formation [58]. Additionally, these injections can result in localized muscle weakness or exacerbate pre-existing symptoms such as dysphagia or dysarthria [59].

For patients who do not respond to noninvasive treatments, deep brain stimulation (DBS) may be considered [60]. This surgical procedure involves the implantation of electrodes into specific brain regions, such as the subthalamic nucleus or globus pallidus internus, to modulate neural activity and alleviate dystonic symptoms [61]. DBS is typically recommended for patients with severe, refractory Meige syndrome who have not responded to medical treatments or botulinum toxin injections. When botulinum toxin and other conservative therapies fail to yield satisfactory results, DBS targeting the globus pallidus interna becomes an effective alternative [62]. Precise electrode placement is critical, with the ventral and posterior segments of the globus pallidus interna being targeted for facial-related symptoms, while the cervicofacial area is positioned more anteriorly [63]. Surgical interventions may also be considered for select cases that are unresponsive to medical or local therapies, with the goal of improving both functional and aesthetic outcomes [64]. Research has demonstrated that combining blepharoplasty with selective myectomy and myotomy can lead to significant and sustained improvements for patients with refractory Meige syndrome [65][66][67].

Differential Diagnosis

When diagnosing Meige syndrome, clinicians must consider a wide array of differential diagnoses due to the overlapping features of various conditions that may present similarly. These include xeromas, spinocerebellar ataxia, progressive supranuclear palsy, tardive dyskinesia, Wilson disease, ischemic stroke, autoimmune or inflammatory conditions such as multiple sclerosis, lupus erythematosus, and Behçet disease, metabolic disorders including hypoxia and pontine myelinolysis, neoplasms such as meningioma and metastatic tumors, myoclonus-dystonia syndrome, facial tic disorders, psychogenic craniocervical dystonia, Parkinson disease, hemifacial spasm, generalized anxiety disorder, and secondary dystonias. Each of these conditions should be carefully considered and excluded as part of the diagnostic process for Meige syndrome to ensure appropriate and accurate clinical management.

Prognosis

The prognosis for individuals with Meige syndrome is highly variable, influenced by the severity of the symptoms, the response to treatment, and any underlying etiological factors. Although Meige syndrome is a chronic condition with the potential to significantly impair quality of life, many patients show improvement in their symptoms when managed appropriately. The dystonic manifestations of Meige syndrome can range from mild, intermittent contractions to severe, continuous symptoms that can be debilitating. The extent of functional impairment and its effects on day-to-day activities can affect the success of treatment and the overall outlook. The prognosis is significantly shaped by the effectiveness of therapeutic interventions such as medications, botulinum toxin injections, and surgical options. While botulinum toxin can often provide symptom relief and improved motor function, responses to treatment vary, and some patients may require a combination of therapies to achieve optimal results. The progression of Meige syndrome is generally slow or stable, with some individuals experiencing a gradual worsening of symptoms, while others may maintain a steady state. Monitoring the disease's progression and the patient's response to treatment is essential for optimizing long-term outcomes and making necessary adjustments to the management plan. Prognosis can be further influenced by underlying genetic, metabolic, or structural abnormalities. Secondary dystonias, particularly those associated with neurodegenerative diseases, metabolic disorders, or structural lesions, tend to have a less favorable prognosis. Identifying and addressing these underlying causes is crucial for guiding treatment decisions and managing prognostic expectations effectively. With proper care, many individuals with Meige syndrome can maintain an acceptable quality of life, as multidisciplinary approaches combining medical treatment, botulinum toxin injections, physical therapy, and supportive care help alleviate symptoms, improve functional outcomes, and enhance overall well-being.

Complications

Meige syndrome, like other forms of dystonia, can lead to a variety of complications that impact the patient's physical, psychological, and social well-being. These complications often stem from the chronic nature of the condition and its profound effects on daily functioning. Common issues include functional impairment, discomfort or pain, difficulties with speech and swallowing, social isolation, stigma, psychological distress, adverse drug reactions, and challenges related to treatment outcomes. The multifaceted nature of these complications can severely reduce the quality of life for both patients and their caregivers. Therefore, a comprehensive, multidisciplinary treatment approach that integrates medical care, rehabilitative interventions, psychological support, and social assistance is essential for effectively managing Meige syndrome. Implementing strategies to minimize these complications, enhance functional outcomes, and improve overall quality of life can significantly benefit those affected by the disorder.

Patient Education

Comprehensive patient education plays a critical role in the management of Meige syndrome, enhancing patient adherence to treatment regimens and helping minimize complications. Educating patients about their condition, including the underlying causes, symptoms, potential impacts on daily life, available treatments, and coping strategies, empowers them to make informed decisions and engage actively in their

care. Patients should be made aware of the pathophysiology of Meige syndrome, particularly how neurotransmitter imbalances contribute to dystonic symptoms and how dysfunctional basal ganglia-thalamocortical circuits exacerbate these manifestations. Providing clear explanations of these biological mechanisms can help alleviate misconceptions and foster a sense of control over the condition. It is also crucial that patients become familiar with the signs and symptoms of Meige syndrome, such as muscle spasms in the face, jaw, and neck, difficulties with speech, and functional impairments, so they can promptly report any changes to their healthcare providers. Early recognition of symptoms can facilitate quicker intervention and management. Active patient involvement in discussions about treatment options—such as botulinum toxin injections, surgery, supportive therapies, and oral medications—is essential. Each treatment modality offers distinct benefits and drawbacks, and shared decision-making should be a priority, ensuring that the selected approach aligns with the patient's goals and preferences. In particular, patients receiving botulinum toxin injections should be thoroughly informed about the procedure, the expected benefits, possible side effects, and the importance of follow-up care, including monitoring for adverse reactions or muscle weakness. Adherence to the prescribed treatment regimen, including regular follow-up appointments, medication schedules, and physical therapy exercises, is vital for maximizing treatment outcomes and preventing exacerbations of the condition. Challenges such as medication side effects, financial constraints, or practical obstacles can hinder adherence, and addressing these barriers is crucial to ensure effective management of the syndrome. Encouraging patients to adopt a healthy lifestyle can further improve their overall well-being and contribute to symptom management. This includes stress reduction, regular physical activity, adequate rest, and dietary considerations, as well as avoiding known triggers like alcohol or caffeine. Supporting patients in tracking their symptoms and developing strategies to cope with dystonic movements can empower them to take an active role in managing their condition. Addressing the emotional and social aspects of Meige syndrome through support networks, counseling services, and peer groups can offer essential psychological support, foster solidarity, and provide practical advice on overcoming the challenges associated with the condition.

Other Issues

The effective management of Meige syndrome necessitates a multifaceted approach, demanding both expertise and individualized care strategies. Clinical insights offer crucial guidance for healthcare providers dealing with this complex neurological disorder, from early detection to customized treatment plans and patient education. Early identification of key symptoms, such as blepharospasm and oromandibular dystonia, is fundamental in ensuring prompt diagnosis and initiating appropriate intervention. Crafting treatment strategies that are specifically tailored to each patient's needs and treatment responses, including options like botulinum toxin injections and deep brain stimulation (DBS), is essential for achieving optimal outcomes. Regular monitoring of symptoms, treatment efficacy, and the detection of any potential adverse effects plays a critical role in the long-term management of Meige syndrome, allowing for the fine-tuning of treatment protocols as required. Incorporating complementary therapies, including physical therapy, speech therapy, and psychological support, is beneficial in enhancing patients' overall functional capacity and quality of life. The involvement of a multidisciplinary healthcare team—comprising neurologists, ophthalmologists, rehabilitation specialists, and speech therapists—ensures coordinated care and facilitates the best possible patient outcomes. Patients should be thoroughly counseled about potential treatment-related side effects, such as muscle weakness or exacerbation of dysphagia, to manage their expectations and mitigate complications. Additionally, providing comprehensive patient education about the condition, its treatment modalities, and possible complications is vital in empowering patients to actively engage in their own care process.

Enhancing Healthcare Team Outcomes

Patients suffering from Meige syndrome derive the greatest benefit from a collaborative, interprofessional approach, which includes primary care clinicians, neurologists, neurosurgeons, pharmacists, nurses, social workers, and other specialists. Early intervention is crucial to minimize morbidity and optimize patient outcomes in this condition. Present treatment options for Meige syndrome encompass oral medications, botulinum toxin therapy, DBS, and, in cases of treatment resistance, surgical interventions. Nurses play an

indispensable role in patient education, ensuring clear communication across the healthcare team. Pharmacists are essential for reviewing both causative and therapeutic medications, identifying potential drug interactions, and providing detailed guidance on medication administration. The application of evidence-based strategies maximizes the effectiveness of treatment regimens while minimizing the risk of adverse effects. Ethical principles guide the treatment process, safeguarding patient autonomy and ensuring that informed consent is obtained for all interventions. It is imperative for all healthcare professionals involved to fully comprehend their specific roles within the multidisciplinary care team. Effective interprofessional communication fosters the seamless exchange of information and collaborative decision-making, enhancing patient care. Furthermore, coordinated care is crucial for managing the patient's entire healthcare journey—from diagnosis to treatment and follow-up—thus improving patient safety, reducing the likelihood of errors, and optimizing clinical outcomes. By upholding core principles such as expertise, strategy, ethical conduct, communication, and coordination, healthcare professionals can provide a patient-centered approach that leads to enhanced outcomes and improved team performance.

Conclusion:

Meige syndrome is a focal dystonia that affects the facial and oromandibular muscles, leading to involuntary movements such as blepharospasm and jaw dystonia. The precise etiology remains poorly understood, though it is believed to be a complex interaction between genetic predispositions and environmental factors. Research has identified mutations in genes like GNAL and TOR1A as potential contributors to the syndrome, although further studies are required to better understand the genetic basis of the disorder. The clinical presentation of Meige syndrome can be highly variable, with symptoms often beginning in adulthood, typically in the 30-70 age range, and progressing over time. Most individuals experience initial symptoms as facial or jaw spasms, which may later involve the neck or other parts of the body. While some patients show spontaneous improvement or remission, the course of the disease is unpredictable, making early diagnosis and intervention essential for managing symptoms and preventing progression. In terms of treatment, pharmacological interventions such as botulinum toxin injections and medications that modulate dopamine and GABA are commonly used to alleviate symptoms. However, the treatment response can vary, and managing side effects remains a challenge. In addition to pharmacological therapies, physical therapy plays a significant role in improving motor control and quality of life. Psychosocial support is also essential to address the emotional and psychological burden that the condition may impose on patients. Nursing interventions are critical in supporting patients with Meige syndrome. Nurses should educate patients about the nature of the disorder and its progression, as well as guide them through various coping strategies and self-management techniques. Physical therapy and psychological support should be integrated into care plans to improve functional outcomes and overall well-being. In conclusion, Meige syndrome remains a complex disorder with no definitive cure. However, with appropriate multidisciplinary management, including pharmacological treatment, physical therapy, and nursing interventions, individuals with Meige syndrome can experience improved quality of life and better symptom control. Further research into the genetic and environmental causes of the disorder is crucial for developing more effective and targeted treatments.

References:

1. Wang X, Mao Z, Cui Z, Xu X, Pan L, Liang S, Ling Z, Yu X. Predictive factors for long-term clinical outcomes of deep brain stimulation in the treatment of primary Meige syndrome. J Neurosurg. 2020 May 01;132(5):1367-1375.
2. Marion MH. Henry Meige: The man and his understanding of dystonia, at the turn of the 19th to 20th century. Rev Neurol (Paris). 2022 Jun;178(6):532-538.
3. Tolosa E, Kulisevsky J, Fahn S. Meige syndrome: primary and secondary forms. Adv Neurol. 1988;50:509-15.
4. LeDoux MS. Meige syndrome: what's in a name? Parkinsonism Relat Disord. 2009 Aug;15(7):483-9.
5. Sellal F, Frismand S. Cervico-facial dystonia as depicted in sculpture before its scientific description. Rev Neurol (Paris). 2019 Mar;175(3):198-200.

6. Aires A, Gomes T, Linhares P, Cunha F, Rosas MJ, Vaz R. The impact of deep brain stimulation on health related quality of life and disease-specific disability in Meige Syndrome (MS). Clin Neurol Neurosurg. 2018 Aug;171:53-57.
7. Jana N, Barik S, Arora N. Current use of medical eponyms--a need for global uniformity in scientific publications. BMC Med Res Methodol. 2009 Mar 09;9:18.
8. Ayesu K, Nguyen B, Harris S, Carlan S. The case for consistent use of medical eponyms by eliminating possessive forms. J Med Libr Assoc. 2018 Jan;106(1):127-129.
9. Lurie S. Meigs' syndrome: the history of the eponym. Eur J Obstet Gynecol Reprod Biol. 2000 Oct;92(2):199-204.
10. Zheng W, Lv G, Lu Y, Liu J, Hao Q, Ding H, Liu Y, Liu R. Bilateral Pallidal Deep Brain Stimulation in Meige Syndrome: Effects on Motor Function, Neuropsychological Status, and Mood. Neurosurgery. 2023 May 01;92(5):1073-1079.
11. Eftekhari K, Choe CH, Vagefi MR, Gausas RE, Eckstein LA. Oral methylphenidate for the treatment of refractory facial dystonias. Ophthalmic Plast Reconstr Surg. 2015 May-Jun;31(3):e65-6.
12. Younce JR, Cascella RH, Berman BD, Jinnah HA, Bellows S, Feuerstein J, Wagle Shukla A, Mahajan A, Chang FCF, Duque KR, Reich S, Richardson SP, Deik A, Stover N, Luna JM, Norris SA. Anatomical categorization of isolated non-focal dystonia: novel and existing patterns using a data-driven approach. Dystonia. 2023;2
13. Balint B, Bhatia KP. Dystonia: an update on phenomenology, classification, pathogenesis and treatment. Curr Opin Neurol. 2014 Aug;27(4):468-76.
14. Pedrero-Escalas MF, García-López I, Santiago-Pérez S, Vivancos F, Gavilán J. Clinical experience with patients with spasmodic dysphonia and primary Meige syndrome. Acta Otorrinolaringol Esp (Engl Ed). 2019 Jan-Feb;70(1):1-5.
15. Jochim A, Li Y, Gora-Stahlberg G, Mantel T, Berndt M, Castrop F, Dresel C, Haslinger B. Altered functional connectivity in blepharospasm/orofacial dystonia. Brain Behav. 2018 Jan;8(1):e00894.
16. Horisawa S, Ochiai T, Goto S, Nakajima T, Takeda N, Kawamata T, Taira T. Long-term outcome of pallidal stimulation for Meige syndrome. J Neurosurg. 2019 Jan 01;130(1):84-89.
17. Kumar KR, Lohmann K, Masuho I, Miyamoto R, Ferbert A, Lohnau T, Kasten M, Hagenah J, Brüggemann N, Graf J, Münchau A, Kostic VS, Sue CM, Domingo AR, Rosales RL, Lee LV, Freimann K, Westenberger A, Mukai Y, Kawarai T, Kaji R, Klein C, Martemyanov KA, Schmidt A. Mutations in GNAL: a novel cause of craniocervical dystonia. JAMA Neurol. 2014 Apr;71(4):490-4.
18. Fan, Y., Si, Z., Wang, L., & Zhang, L. (2023). DYT-TOR1A dystonia: an update on pathogenesis and treatment. *Frontiers in Neuroscience*, *17*, 1216929.
19. Garofalo, M., Beudel, M., Dijk, J. M., Bonouvrié, L. A., Buizer, A. I., Geytenbeek, J., ... & van de Pol, L. A. (2023). Elective and emergency deep brain stimulation in refractory pediatric monogenetic movement disorders presenting with dystonia: current practice illustrated by two cases. *Neuropediatrics*, *54*(01), 044-052.
20. Arzul L, Henoux M, Marion F, Corre P. [Bilateral chronic dislocation of the temporomandibular joints and Meige syndrome]. Rev Stomatol Chir Maxillofac Chir Orale. 2015 Apr;116(2):106-10.
21. Gautam P, Bhatia MS, Kaur J, Rathi A. Meige's syndrome. Ind Psychiatry J. 2016 Jul-Dec;25(2):232-233.
22. Gn S, Nag A. Management of Oromandibular Dystonia: A Case Report and Literature Update. Case Rep Dent. 2017;2017:3514393.
23. O'Riordan S, Raymond D, Lynch T, Saunders-Pullman R, Bressman SB, Daly L, Hutchinson M. Age at onset as a factor in determining the phenotype of primary torsion dystonia. Neurology. 2004 Oct 26;63(8):1423-6.
24. Scorr LM, Cho HJ, Kilic-Berkmen G, McKay JL, Hallett M, Klein C, Baumer T, Berman BD, Feuerstein JS, Perlmutter JS, Berardelli A, Ferrazzano G, Wagle-Shukla A, Malaty IA, Jankovic J, Bellows ST, Barbano RL, Vidailhet M, Roze E, Bonnet C, Mahajan A, LeDoux MS, Fung VSC, Chang FCF, Defazio G, Ercoli T, Factor S, Wojno T, Jinnah HA. Clinical Features and Evolution of Blepharospasm: A Multicenter International Cohort and Systematic Literature Review. Dystonia. 2022;1

25. Pandey S, Sharma S. Meige's syndrome: History, epidemiology, clinical features, pathogenesis and treatment. J Neurol Sci. 2017 Jan 15;372:162-170.
26. Defazio G, Abbruzzese G, Livrea P, Berardelli A. Epidemiology of primary dystonia. Lancet Neurol. 2004 Nov;3(11):673-8.
27. Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group. A prevalence study of primary dystonia in eight European countries. J Neurol. 2000 Oct;247(10):787-92.
28. Defazio G, Livrea P. Epidemiology of primary blepharospasm. Mov Disord. 2002 Jan;17(1):7-12.
29. Jankovic J, Orman J. Blepharospasm: demographic and clinical survey of 250 patients. Ann Ophthalmol. 1984 Apr;16(4):371-6.
30. Zhan S, Sun F, Pan Y, Liu W, Huang P, Cao C, Zhang J, Li D, Sun B. Bilateral deep brain stimulation of the subthalamic nucleus in primary Meige syndrome. J Neurosurg. 2018 Mar;128(3):897-902.
31. Cabuk KS, Coban G, Yalcinkaya Cakir G, Sezal Serefoglu Z, Asik Nacaroglu S, Ozturk Karabulut G, Fazil K. Histopathological View of Benign Essential Blepharospasm: Orbicularis Oculi Hormone Receptor Levels. Beyoglu Eye J. 2023;8(2):110-114.
32. Ma H, Qu J, Ye L, Shu Y, Qu Q. Blepharospasm, Oromandibular Dystonia, and Meige Syndrome: Clinical and Genetic Update. Front Neurol. 2021;12:630221.
33. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology. 1988 Mar;38(3):391-4.
34. Yoshimura R, Kakihara S, Soya A, Ueda N, Shinkai K, Nakamura J. Effect of clonazepam treatment on antipsychotic drug-induced Meige syndrome and changes in plasma levels of GABA, HVA, and MHPG during treatment. Psychiatry Clin Neurosci. 2001 Oct;55(5):543-6.
35. Lee SA, Kim JS, Ahn JH, Choi KG. Sulpiride in Meige's syndrome: possible role of glutamate. Yonsei Med J. 1988;29(1):62-5.
36. Piccinin CC, Piovesana LG, Santos MC, Guimarães RP, De Campos BM, Rezende TJ, Campos LS, Torres FR, Amato-Filho AC, França MC, Lopes-Cendes I, Cendes F, D'Abreu A. Diffuse decreased gray matter in patients with idiopathic craniocervical dystonia: a voxel-based morphometry study. Front Neurol. 2014;5:283.
37. Valls-Sole J, Defazio G. Blepharospasm: Update on Epidemiology, Clinical Aspects, and Pathophysiology. Front Neurol. 2016;7:45.
38. Fan Y, Si Z, Wang L, Zhang L. DYT-*TOR1A* dystonia: an update on pathogenesis and treatment. Front Neurosci. 2023;17:1216929.
39. Kim S, Phan S, Shaw TR, Ellisman MH, Veatch SL, Barmada SJ, Pappas SS, Dauer WT. TorsinA is essential for the timing and localization of neuronal nuclear pore complex biogenesis. bioRxiv. 2023 Apr 27;
40. Pandey S, Bhattad S, Dinesh S. Tremor in Primary Monogenic Dystonia. Curr Neurol Neurosci Rep. 2021 Jul 15;21(9):48.
41. Wang, X., Mao, Z., & Yu, X. (2023). Volume of tissue activated within subthalamic nucleus and clinical efficacy of deep brain stimulation in Meige syndrome. *Neurological Sciences*, *44*(5), 1643-1651.
42. Peckham EL, Lopez G, Shamim EA, Richardson SP, Sanku S, Malkani R, Stacy M, Mahant P, Crawley A, Singleton A, Hallett M. Clinical features of patients with blepharospasm: a report of 240 patients. Eur J Neurol. 2011 Mar;18(3):382-6.
43. Broussolle E, Laurencin C, Bernard E, Thobois S, Danaila T, Krack P. Early Illustrations of Geste Antagoniste in Cervical and Generalized Dystonia. Tremor Other Hyperkinet Mov (N Y). 2015;5:332.
44. Marsden CD. Blepharospasm-oromandibular dystonia syndrome (Brueghel's syndrome). A variant of adult-onset torsion dystonia? J Neurol Neurosurg Psychiatry. 1976 Dec;39(12):1204-9.
45. Liu B, Mao Z, Cui Z, Ling Z, Xu X, He K, Cui M, Feng Z, Yu X, Zhang Y. Cerebellar gray matter alterations predict deep brain stimulation outcomes in Meige syndrome. Neuroimage Clin. 2023;37:103316.
46. Huang C, Miao S, Chu H, Muheremu A, Wu J, Zhou R, Zuo H, Ma Y. Application of electrophysiological methods and magnetic resonance tomographic angiography in the differentiation between hemifacial spasm and Meige syndrome. Neurol Sci. 2016 May;37(5):769-75.
47. Teng X, Qu Q, Shu Y, Gong J, Xu B, Qu J. Genetic screening in patients of Meige syndrome and blepharospasm. Neurol Sci. 2022 Jun;43(6):3683-3694.

48. Liu J, Ding H, Liu R. Mutation of ADCY5 gene in patients with Meige syndrome. Asian J Surg. 2022 Jul;45(7):1487-1488.
49. Guan H, Geng Z, Yuan W, Chang B. Association of Serum Uric Acid Levels in Meige's Syndrome. Front Neurosci. 2021;15:755056.
50. Tamás G, Abrantes C, Valadas A, Radics P, Albanese A, Tijssen MAJ, Ferreira JJ. Quality and reporting of guidelines on the diagnosis and management of dystonia. Eur J Neurol. 2018 Feb;25(2):275-283.
51. Jinnah HA, Factor SA. Diagnosis and treatment of dystonia. Neurol Clin. 2015 Feb;33(1):77-100.
52. Karp BI. Botulinum toxin physiology in focal hand and cranial dystonia. Toxins (Basel). 2012 Nov 20;4(11):1404-14.
53. Sobstyl M, Ząbek M. [Deep brain stimulation in the treatment of torticollis and Meige syndrome]. Neurol Neurochir Pol. 2011 Nov-Dec;45(6):590-9.
54. Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, Armstrong MJ, Gloss D, Potrebic S, Jankovic J, Karp BP, Naumann M, So YT, Yablon SA. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016 May 10;86(19):1818-26.
55. Hassell TJW, Charles D. Treatment of Blepharospasm and Oromandibular Dystonia with Botulinum Toxins. Toxins (Basel). 2020 Apr 22;12(4)
56. Karp BI, Alter K. Botulinum Toxin Treatment of Blepharospasm, Orofacial/Oromandibular Dystonia, and Hemifacial Spasm. Semin Neurol. 2016 Feb;36(1):84-91.
57. Duarte, A., Coutinho, L., Germiniani, F. M. B., & Teive, H. A. G. (2023). Effects of Onabotulinum toxin type A in patients with Meige's syndrome (P12-11.003). *Neurology*, *100*(17_supplement_2), 4720.
58. Duarte, A., Coutinho, L., Germiniani, F. M. B., & Teive, H. A. G. (2023). Effects of Onabotulinum toxin type A in patients with Meige's syndrome (P12-11.003). *Neurology*, *100*(17_supplement_2), 4720.
59. Zheng H, Wu L, Tian S, Liu M, Zhan Q, Yu X, Xie Y, Zhong X, Wu W. Effect of botulinum toxin type A on non-motor symptoms and quality of life in Meige syndrome. Front Neurol. 2023;14:1115482.
60. Rodrigues FB, Duarte GS, Prescott D, Ferreira J, Costa J. Deep brain stimulation for dystonia. Cochrane Database Syst Rev. 2019 Jan 10;1(1):CD012405.
61. Aragão VT, Barbosa Casagrande SC, Listik C, Teixeira MJ, Barbosa ER, Cury RG. Rescue Subthalamic Deep Brain Stimulation for Refractory Meige Syndrome. Stereotact Funct Neurosurg. 2021;99(5):451-453.
62. Odorfer TM, Volkmann J. Deep Brain Stimulation for Focal or Segmental Craniocervical Dystonia in Patients Who Have Failed Botulinum Neurotoxin Therapy-A Narrative Review of the Literature. Toxins (Basel). 2023 Oct 09;15(10)
63. Limotai N, Go C, Oyama G, Hwynn N, Zesiewicz T, Foote K, Bhidayasiri R, Malaty I, Zeilman P, Rodriguez R, Okun MS. Mixed results for GPi-DBS in the treatment of cranio-facial and cranio-cervical dystonia symptoms. J Neurol. 2011 Nov;258(11):2069-74.
64. Lai CS, Ramachandran S, Lee CC, Lai YW, Chang YP, Huang SH. Evaluation of Blepharoptosis in Patients With Refractory Blepharospasm by VISA-Video Recordings, Idiosyncratic Expressions, Sensory Tricks, and Ancillary Procedures. Ann Plast Surg. 2023 May 01;90(5S Suppl 2):S172-S176.
65. Pariseau B, Worley MW, Anderson RL. Myectomy for blepharospasm 2013. Curr Opin Ophthalmol. 2013 Sep;24(5):488-93.
66. Lai HT, Chen AD, Lee SS, Lin YH, Lai CS. Myotomy In Situ for Essential Blepharospasm Refractory to Botulinum Toxin. Ann Plast Surg. 2020 Jan;84(1S Suppl 1):S74-S79.
67. Lai CS, Wang YC, Ramachandran S, Chang YP, Huang SH, Hsieh MW. Selective Myectomy and Myotomy In Situ for the Management of Refractory Blepharospasm in Meige Syndrome. Ann Plast Surg. 2023 Apr 01;90(1 Suppl 1):S84-S88.

الملخص:

الخلفية: متلازمة ميج هي اضطراب خلل التوتر الفوكل النادر الذي يتميز بالتشنجات الجفنية (التشنجات اللاإرادية للجفون) والتوتر العضلي الفكي الفموي (التشنجات في عضلات الفك والوجه). تم وصفها لأول مرة من قبل الدكتور هنري ميج في عام 1910، وتم تسميتها لاحقًا من قبل الدكتور جورج بولسون في عام 1972. لا يزال السبب الدقيق لهذه المتلازمة غير واضح. يُعتقد أنها تنشأ نتيجة لاضطرابات في أنظمة النواقل العصبية، خاصة الدوبامين وحمض الغاما-أمينوبيوتيريك(GABA) ، التي تشمل العقد القاعدية، وهي منطقة حيوية في الدماغ تتحكم في الحركة.

الهدف: يهدف هذا الاستعراض إلى تقديم فهم محدث لمتلازمة ميج، بما في ذلك وفسيولوجيتها المرضية، عرضها السريري، خيارات العلاج الدوائي، استراتيجيات الإدارة، وكذلك التدخلات التمريضية لتحسين نتائج المرضى.

الطرق: تم إجراء مراجعة شاملة للأدبيات ذات الصلة، مع التركيز على الأسباب الأولية والثانوية لمتلازمة ميج، وبائيتها، وفسيولوجيتها المرضية، واستراتيجيات العلاج. تم مناقشة العلاجات الدوائية المختلفة، بما في ذلك حقن سم البوتولينوم والعلاج الدوباميني، إلى جانب أحدث النتائج المتعلقة بالعوامل الوراثية والبيئية التي تساهم في تطور الاضطراب.

النتائج: تؤثر متلازمة ميج بشكل رئيسي على الأفراد الذين تتراوح أعمارهم بين 30 و70 عامًا، مع زيادة في الإصابة لدى الإناث. تبدأ الأعراض عادةً بتوتر في الفك والوجه وقد تتقدم لتشمل الرقبة والعضلات الأخرى. تساهم الطفرات الوراثية) مثل الطفرات في جينات GNAL و TOR1A)والعوامل البيئية (مثل التوتر أو استخدام الأدوية النفسية) في ظهور المتلازمة. تُظهر العلاجات الدوائية مثل حقن سم البوتولينوم والأدوية التي تعدل الدوبامين وعودًا في إدارة الأعراض. يعد العلاج الطبيعي والدعم النفسي الاجتماعي أمرين أساسيين للرعاية الشاملة.

الخاتمة: على الرغم من أن آلية نشوء متلازمة ميج تظل معقدة، فإن العلاجات الدوائية وغير الدوائية يمكن أن تحسن بشكل كبير من إدارة الأعراض. لا يزال البحث المستمر في التفاعلات الوراثية والبيئية أمرًا ضروريًا لتطوير علاجات أكثر فعالية. يلعب الإدارة متعددة التخصصات، بما في ذلك التدخلات التمريضية، دورًا حيويًا في تحسين جودة الحياة للأفراد المصابين بمتلازمة ميج.

الكلمات المفتاحية: متلازمة ميج، خلل التوتر، التشنجات الجفنية، خلل التوتر الفكي الفموي، العلاج الدوائي، التدخلات التمريضية، العقد القاعدية، النواقل العصبية، سم البوتولينوم.